Clayton Emma L, Mizielinska Sarah, Edgar James R, Nielsen Troels Tolstrup, Marshall Sarah, Norona Frances E, Robbins Miranda, Damirji Hana, Holm Ida E, Johannsen Peter, Nielsen Jørgen E, Asante Emmanuel A, Collinge John, Isaacs Adrian M
Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
Cambridge Institute for Medical Research, University of Cambridge, Cambridge, CB2 0XY, UK.
Acta Neuropathol. 2015 Oct;130(4):511-23. doi: 10.1007/s00401-015-1475-3. Epub 2015 Sep 10.
Mutations in the charged multivesicular body protein 2B (CHMP2B) cause frontotemporal dementia (FTD). We report that mice which express FTD-causative mutant CHMP2B at physiological levels develop a novel lysosomal storage pathology characterised by large neuronal autofluorescent aggregates. The aggregates are an early and progressive pathology that occur at 3 months of age and increase in both size and number over time. These autofluorescent aggregates are not observed in mice expressing wild-type CHMP2B, or in non-transgenic controls, indicating that they are a specific pathology caused by mutant CHMP2B. Ultrastructural analysis and immuno- gold labelling confirmed that they are derived from the endolysosomal system. Consistent with these findings, CHMP2B mutation patient brains contain morphologically similar autofluorescent aggregates. These aggregates occur significantly more frequently in human CHMP2B mutation brain than in neurodegenerative disease or age-matched control brains. These data suggest that lysosomal storage pathology is the major neuronal pathology in FTD caused by CHMP2B mutation. Recent evidence suggests that two other genes associated with FTD, GRN and TMEM106B are important for lysosomal function. Our identification of lysosomal storage pathology in FTD caused by CHMP2B mutation now provides evidence that endolysosomal dysfunction is a major degenerative pathway in FTD.
带电荷多囊泡体蛋白2B(CHMP2B)的突变会导致额颞叶痴呆(FTD)。我们报告称,在生理水平表达导致FTD的突变型CHMP2B的小鼠会出现一种新型溶酶体贮积病理,其特征为神经元中出现大量自发荧光聚集体。这些聚集体是一种早期且进行性的病理变化,在3个月大时出现,并随着时间推移在大小和数量上都有所增加。在表达野生型CHMP2B的小鼠或非转基因对照小鼠中未观察到这些自发荧光聚集体,这表明它们是由突变型CHMP2B引起的特异性病理变化。超微结构分析和免疫金标记证实它们源自内溶酶体系统。与这些发现一致,CHMP2B突变患者的大脑中含有形态相似的自发荧光聚集体。这些聚集体在人类CHMP2B突变大脑中出现的频率明显高于神经退行性疾病或年龄匹配的对照大脑。这些数据表明,溶酶体贮积病理是CHMP2B突变导致的FTD中的主要神经元病理。最近的证据表明,与FTD相关的另外两个基因GRN和TMEM106B对溶酶体功能很重要。我们在CHMP2B突变导致的FTD中鉴定出溶酶体贮积病理,现在为内溶酶体功能障碍是FTD中的主要退行性途径提供了证据。